Verheijen R, Van den Hoogen F, Beijer R, Richter A, Penner E, Habets W J, van Venrooij W J
Department of Biochemistry, University of Nijmegen, The Netherlands.
Clin Exp Immunol. 1990 Apr;80(1):38-43. doi: 10.1111/j.1365-2249.1990.tb06438.x.
We report the expression of a cDNA clone encoding 695 carboxyl-terminal amino acids of human DNA topoisomerase I (topoI) in Escherichia coli. More than 96% of the anti-HeLa topoI-positive sera from patients with a connective tissue disease displayed also an immunoreactivity with this recombinant protein (the HTopoA protein). Sera from patients with a definite diagnosis systemic sclerosis and reacting with HeLa topoI, all reacted with the HTopoA protein as well. Sera from patients with systemic sclerosis that did not contain anti-topoI antibodies (about 30% of the systemic sclerosis sera), as concluded from HeLa immunoblot, displayed also no immunoreactivity with our recombinant antigen. By expressing different fragments of HTopoA, we were able to assign at least three different autoimmune epitope regions on the HTopoA protein and we show that over a period of 5 years the amount of anti-topoI antibodies against these regions may fluctuate.
我们报道了编码人DNA拓扑异构酶I(拓扑异构酶I)羧基末端695个氨基酸的cDNA克隆在大肠杆菌中的表达。来自结缔组织病患者的超过96%的抗HeLa拓扑异构酶I阳性血清也与这种重组蛋白(HTopoA蛋白)表现出免疫反应性。明确诊断为系统性硬化症且与HeLa拓扑异构酶I反应的患者血清,也均与HTopoA蛋白反应。从HeLa免疫印迹得出,不含抗拓扑异构酶I抗体的系统性硬化症患者血清(约占系统性硬化症血清的30%),与我们的重组抗原也无免疫反应性。通过表达HTopoA的不同片段,我们能够在HTopoA蛋白上确定至少三个不同的自身免疫表位区域,并且我们表明在5年的时间里,针对这些区域的抗拓扑异构酶I抗体量可能会波动。